The much-discussed US v. Caronia case, which has raised questions about the Food and Drug Administration prosecution of pharma companies for making off-label product claims, doesn’t change very much, according to FDA’s top drug marketing enforcer.
Posted in Advertising, Agency Insight, E-Media, FDA, Legal, Marketing, Regulatory, leadership, social media | Also tagged CBI, FDA, First Amendment, off-label, OPDP, Tom Abrams, US v. Caronia
PharmExec Blog
Follow Us
RSS
Bookstore
Tom Abrams: Caronia Won't Stop Off-Label Enforcement